SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, today announced a collaboration with the University of California, Irvine to evaluate biomarkers detected from blood-based versus invasive tissue biopsies in patients with metastatic cancers. The collaboration is aimed at validating the use of liquid biopsies to qualify patients for available targeted therapies and to establish a framework for serial monitoring of tumor mutations during cancer treatment to help identify early indicators of resistance to therapy.
Help employers find you! Check out all the jobs and post your resume.
